A pharmaceutical company wanted to understand what specifically influences pharmacotherapy decisions and pathways when transitioning patients with a neurodivergent diagnosis, from childhood to adulthood. Their aim was to understand disease management and lived experiences from individuals diagnosed with this specific neurodivergent diagnosis as children and their pain points specifically around their early adulthood transition and, what influenced medication continuation vs. discontinuation.
RESEARCH STRATEGY GROUP uncovered cognitive biases that were shaping decision making. We were able to provide strategic recommendations on how to enable patients with this specific neurodivergent condition to take better control of their life, ensure they are supported throughout their journey, set realistic treatment expectations, and better facilitate a sense of trust between patients and physicians.
Our team employed behavioural science & traditional research discourse through in person and web-assisted IDIs with people (parents and adult patients) with this specific neurodivergent diagnosis.
About methodology used: